Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences.

Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences, Inc. Applications are also submitted to the next other Concerned Member Claims in the European Union: Austria, France, Germany, Italy, Portugal and Spain Get more information . Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Begin GeneticsDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya Das’This MAA submission carefully comes after the submission of our NDA to the U.S. Drug and Food Administration last week, and marks an important first step toward the option of a sustained release treatment for DME sufferers in Europe,’ said Dan Myers, president and CEO of Alimera.